Guro F. Giskeødegård

Guro F. Giskeødegård

orcid

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 December 2014 in BMC Cancer
Verified
Journal Article
Open access
PDF file
MCMaria D Cao
Maria D Cao
Santosh LamichhaneSantosh Lamichhane
Santosh Lamichhane
SLSteinar Lundgren
Steinar Lundgren
ABAnna Bofin
Anna Bofin
HFHans Fjøsne
Hans Fjøsne
TBTone Frost Bathen
Tone Frost Bathen
The aims of this study were to characterize the metabolite profiles of triple negative breast cancer (TNBC) and to investigate the metabolite profiles associated with human epidermal growth factor receptor-2/neu (HER-2) overexpression using ex vivo high resolution magic angle spinning magnetic resonance spectroscopy (HR MAS MRS). Metabolic alterations caused by the different estrogen receptor (ER), progesterone receptor (PgR) and HER-2 receptor statuses were also examined. To investigate the metabolic differences between two distinct receptor groups, TNBC tumors were compared to tumors with ERpos/PgRpos/HER-2pos status which for the sake of simplicity is called triple positive breast cancer (TPBC).

8 December 2009 in Journal of Proteome Research
Verified
Journal Article
Closed access
GGGuro F. Giskeødegård
Guro F. Giskeødegård
MGMaria T. Grinde
Maria T. Grinde
BSBeathe Sitter
Beathe Sitter
DADavid E. Axelson
David E. Axelson
SLSteinar Lundgren
Steinar Lundgren
TBTone F. Bathen
Tone F. Bathen

29 March 2017 in Breast Cancer Research
Verified
Journal Article
Open access
PDF file
OSOsbreac
Osbreac
MAMiriam Ragle Aure
Miriam Ragle Aure
VVValeria Vitelli
Valeria Vitelli
SJSandra Jernström
Sandra Jernström
SKSurendra Kumar
Surendra Kumar
KSKristine K. Sahlberg
Kristine K. Sahlberg
Breast cancer is a heterogeneous disease at the clinical and molecular level. In this study we integrate classifications extracted from five different molecular levels in order to identify integrated subtypes. Tumor tissue from 425 patients with primary breast cancer from the Oslo2 study was cut and blended, and divided into fractions for DNA, RNA and protein isolation and metabolomics, allowing the acquisition of representative and comparable molecular data. Patients were stratified into groups based on their tumor characteristics from five different molecular levels, using various clustering methods. Finally, all previously identified and newly determined subgroups were combined in a multilevel classification using a “cluster-of-clusters” approach with consensus clustering. Based on DNA copy number data, tumors were categorized into three groups according to the complex arm aberration index. mRNA expression profiles divided tumors into five molecular subgroups according to PAM50 subtyping, and clustering based on microRNA expression revealed four subgroups. Reverse-phase protein array data divided tumors into five subgroups. Hierarchical clustering of tumor metabolic profiles revealed three clusters. Combining DNA copy number and mRNA expression classified tumors into seven clusters based on pathway activity levels, and tumors were classified into ten subtypes using integrative clustering. The final consensus clustering that incorporated all aforementioned subtypes revealed six major groups. Five corresponded well with the mRNA subtypes, while a sixth group resulted from a split of the luminal A subtype; these tumors belonged to distinct microRNA clusters. Gain-of-function studies using MCF-7 cells showed that microRNAs differentially expressed between the luminal A clusters were important for cancer cell survival. These microRNAs were used to validate the split in luminal A tumors in four independent breast cancer cohorts. In two cohorts the microRNAs divided tumors into subgroups with significantly different outcomes, and in another a trend was observed. The six integrated subtypes identified confirm the heterogeneity of breast cancer and show that finer subdivisions of subtypes are evident. Increasing knowledge of the heterogeneity of the luminal A subtype may add pivotal information to guide therapeutic choices, evidently bringing us closer to improved treatment for this largest subgroup of breast cancer.

19 May 2021 in Diabetologia
Verified
Journal Article
Open access
PDF file
TMTrine Moholdt
Trine Moholdt
EPEvelyn Parr
Evelyn Parr
BDBrooke Devlin
Brooke Devlin
JDJulia Debik
Julia Debik
GGGuro F. Giskeødegård
Guro F. Giskeødegård
JHJohn Alan Hawley
John Alan Hawley
Aims/hypothesis: We determined whether the time of day of exercise training (morning vs evening) would modulate the effects of consumption of a high-fat diet (HFD) on glycaemic control, whole-body health markers and serum metabolomics.Methods: In this three-armed parallel-group randomised trial undertaken at a university in Melbourne, Australia, overweight/obese men consumed an HFD (65% of energy from fat) for 11 consecutive days. Participants were recruited via social media and community advertisements. Eligibility criteria for participation were male sex, age 30–45 years, BMI 27.0–35.0 kg/m2and sedentary lifestyle. The main exclusion criteria were known CVD or type 2 diabetes, taking prescription medications, and shift-work. After 5 days, participants were allocated using a computer random generator to either exercise in the morning (06:30 hours), exercise in the evening (18:30 hours) or no exercise for the subsequent 5 days. Participants and researchers were not blinded to group assignment. Changes in serum metabolites, circulating lipids, cardiorespiratory fitness, BP, and glycaemic control (from continuous glucose monitoring) were compared between groups.Results: Twenty-five participants were randomised (morning exercisen = 9; evening exercisen = 8; no exercisen = 8) and 24 participants completed the study and were included in analyses (n = 8 per group). Five days of HFD induced marked perturbations in serum metabolites related to lipid and amino acid metabolism. Exercise training had a smaller impact than the HFD on changes in circulating metabolites, and only exercise undertaken in the evening was able to partly reverse some of the HFD-induced changes in metabolomic profiles. Twenty-four-hour glucose concentrations were lower after 5 days of HFD compared with the participants’ habitual diet (5.3 ± 0.4 vs 5.6 ± 0.4 mmol/l,p = 0.001). There were no significant changes in 24 h glucose concentrations for either exercise group but lower nocturnal glucose levels were observed in participants who trained in the evening, compared with when they consumed the HFD alone (4.9 ± 0.4 vs 5.3 ± 0.3 mmol/l,p = 0.04). Compared with the no-exercise group, peak oxygen uptake improved after both morning (estimated effect 1.3 ml min−1 kg−1[95% CI 0.5, 2.0],p = 0.003) and evening exercise (estimated effect 1.4 ml min−1 kg−1[95% CI 0.6, 2.2],p = 0.001). Fasting blood glucose, insulin, cholesterol, triacylglycerol and LDL-cholesterol concentrations decreased only in participants allocated to evening exercise training. There were no unintended or adverse effects.Conclusions/interpretation: A short-term HFD in overweight/obese men induced substantial alterations in lipid- and amino acid-related serum metabolites. Improvements in cardiorespiratory fitness were similar regardless of the time of day of exercise training. However, improvements in glycaemic control and partial reversal of HFD-induced changes in metabolic profiles were only observed when participants exercise trained in the evening.Trial registration: anzctr.org.auregistration no. ACTRN12617000304336.Funding: This study was funded by the Novo Nordisk Foundation (NNF14OC0011493).Graphical

16 November 2024 in Nature Communications
Verified
Journal Article
Open access
PDF file
AKAntti Kiviaho
Antti Kiviaho
SESini K. Eerola
Sini K. Eerola
HKHeini M. L. Kallio
Heini M. L. Kallio
MAMaria Karoline Andersen
Maria Karoline Andersen
MHMiina Hoikka
Miina Hoikka
MNMatti Nykter
Matti Nykter
Prostate cancer treatment resistance is a significant challenge facing the field. Genomic and transcriptomic profiling have partially elucidated the mechanisms through which cancer cells escape treatment, but their relation toward the tumor microenvironment (TME) remains elusive. Here we present a comprehensive transcriptomic landscape of the prostate TME at multiple points in the standard treatment timeline employing single-cell RNA-sequencing and spatial transcriptomics data from 120 patients. We identify club-like cells as a key epithelial cell subtype that acts as an interface between the prostate and the immune system. Tissue areas enriched with club-like cells have depleted androgen signaling and upregulated expression of luminal progenitor cell markers. Club-like cells display a senescence-associated secretory phenotype and their presence is linked to increased polymorphonuclear myeloid-derived suppressor cell (PMN-MDSC) activity. Our results indicate that club-like cells are associated with myeloid inflammation previously linked to androgen deprivation therapy resistance, providing a rationale for their therapeutic targeting.

25 January 2012 in BMC Cancer
Verified
Journal Article
Open access
PDF file
MCMaria D Cao
Maria D Cao
GGGuro F. Giskeødegård
Guro F. Giskeødegård
TBTone Frost Bathen
Tone Frost Bathen
BSBeathe Sitter
Beathe Sitter
ABAnna Bofin
Anna Bofin
IGIngrid S Gribbestad
Ingrid S Gribbestad
Today's clinical diagnostic tools are insufficient for giving accurate prognosis to breast cancer patients. The aim of our study was to examine the tumor metabolic changes in patients with locally advanced breast cancer caused by neoadjuvant chemotherapy (NAC), relating these changes to clinical treatment response and long-term survival.